Posted by Michael Wonder on 03 Nov 2023
Mounjaro (tirzepatide), the first and only single molecule GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes is now available in Canada
2 November 2023 - Mounjaro represents the first new class of diabetes medicines introduced in nearly a decade and is now available for Canadian patients.
Lilly Canada is pleased to announce that Mounjaro (tirzepatide) is now available in Canada.
Read Eli Lilly press release
Posted by:
Michael Wonder